Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

Naveen Pemmaraju; Natalie C. Chen; Srdan Verstovsek

doi:10.1016/j.hoc.2020.12.007

Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

Naveen Pemmaraju, Natalie C. Chen, Srdan Verstovsek

Leukemia

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.

Original language	English (US)
Pages (from-to)	409-429
Number of pages	21
Journal	Hematology/Oncology Clinics of North America
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/j.hoc.2020.12.007
State	Published - Apr 2021

Keywords

IMiD
Immunotherapy
Interferon ICI
JAK-STAT
MPN

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2020.12.007

Cite this

@article{1fccc6377bcd4ce59416e9f24e423be3,

title = "Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms",

abstract = "Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.",

keywords = "IMiD, Immunotherapy, Interferon ICI, JAK-STAT, MPN",

author = "Naveen Pemmaraju and Chen, {Natalie C.} and Srdan Verstovsek",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = apr,

doi = "10.1016/j.hoc.2020.12.007",

language = "English (US)",

volume = "35",

pages = "409--429",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

AU - Pemmaraju, Naveen

AU - Chen, Natalie C.

AU - Verstovsek, Srdan

PY - 2021/4

Y1 - 2021/4

N2 - Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.

AB - Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.

KW - IMiD

KW - Immunotherapy

KW - Interferon ICI

KW - JAK-STAT

KW - MPN

UR - http://www.scopus.com/inward/record.url?scp=85100233732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100233732&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2020.12.007

DO - 10.1016/j.hoc.2020.12.007

M3 - Review article

C2 - 33641877

AN - SCOPUS:85100233732

SN - 0889-8588

VL - 35

SP - 409

EP - 429

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 2

ER -

Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this